---
title: "Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Pathophysiology"
description: "Formulary evidence on Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Pathophysiology. Topics: Mast cell activation as the central mechanism; Skin mast cells as the primary effector cell, with increased numbers in lesional and non-lesional skin; Other cells, receptors, and pathways: T cells, B cells, eosinophils, basophils, MRGPRX2, complement, and coagulation; Autoimmune endotypes: type I (autoallergic) and type IIb autoimmune CSU; 9 further topics. 13 evidence topics quoted from 13 sources."
canonical: "https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description/pathophysiology"
published: "2026-11-18T22:38:31-05:00"
modified: "2026-11-18T22:38:31-05:00"
---

# Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Pathophysiology

<a id="heading-2.2.1.4"></a>

## 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

### Mast cell activation as the central mechanism

> “Urticaria is predominantly a mast cell‐driven disease but the triggers that activate mast cells are heterogeneous, diverse, and vary from patient to patient”
> “Overall, the result of mast cell activation is the release of mediators such as histamine and platelet activation factor (PAF), among others, which are responsible for sensory nerve stimuli (pruritus), vasodilatation (erythema), and inflammatory cells chemoattraction.”
> “Histologically, wheals are characterized by degranulated mast cells, with edema of the upper‐ and mid‐dermis, with dilatation and augmented permeability of the postcapillary venules as well as lymphatic vessels of the upper dermis.”
> “In angioedema, similar changes occur primarily in the lower dermis and the subcutis.”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

> “It presents with wheals, angioedema or both due to activation and degranulation of skin mast cells and the release of histamine and other mediators.”

Source: [Kolkhir et al. (2022c)](https://pubmed.ncbi.nlm.nih.gov/36109590/)

<a id="topic-2.2.1.4-2"></a>

### Skin mast cells as the primary effector cell, with increased numbers in lesional and non-lesional skin

> “This review presents evidence that the skin mast cell, in particular the MCTC subtype, is the primary effector cell in urticaria.”
> “Increased numbers of mast cells are found in both lesional and non-lesional skin in CSU and inducible urticaria.”
> “Histamine, PGD2 and tryptase are found in the venous blood draining wheal formation.”
> “The last 2 are specific for mast cells rather than basophils.”

Source: [Church et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29431202/)

> “Pathogenically, the skin mast cells are the most important cell in patients with CU, and histamine is the predominant mediator, although other cells and mediators also play a key role.”

Source: [Bernstein et al. (2014)](https://doi.org/10.1016/j.jaci.2014.02.036)

<a id="topic-2.2.1.4-3"></a>

### Other cells, receptors, and pathways: T cells, B cells, eosinophils, basophils, MRGPRX2, complement, and coagulation

> “Other than the histamine receptor, there are other receptors on mast cells that are also involved, such as the Mas‐related G‐protein coupled receptor member X2 (MRGPRX2)”
> “In addition to mast cells, several other cells and mediators can contribute to the pathology of CSU.”
> “These include T cells (i.e., interaction via OX40/OX40L, T cell cytokines), B cells (autoantibody production), eosinophils (i.e., release of MRGPRX2 agonists), neutrophils or basophils, macrophages, sensory nerves (i.e., release of neuropeptides), and others”
> “The non‐lesional skin of CSU patients has been shown to exhibit an upregulation of adhesion molecules, infiltrating eosinophils, altered cytokine expression”
> “Also, a significant number of CSU patients show signs of type 2 inflammation‐driven comorbidities”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

> “The pathogenesis of CSU consists of several interlinked events involving autoantibodies, complement and coagulation.”

Source: [Kolkhir et al. (2022c)](https://pubmed.ncbi.nlm.nih.gov/36109590/)

<a id="topic-2.2.1.4-4"></a>

### Autoimmune endotypes: type I (autoallergic) and type IIb autoimmune CSU

> “In more than 50% of CSU patients, the pathophysiology is driven by two main autoimmune mechanisms: Type I (autoallergy) involving IgE autoantibodies against autoallergens, and type IIb involving IgG autoantibodies; a subpopulation of patients with CSU has both types”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

> “Type I autoimmune (autoallergic) CSU is associated with IgE antibodies against autoantigens, for example, thyroid peroxidase and IL-24.”
> “Type IIb autoimmune CSU is mediated by autoantibodies that activate mast cells, for example, via IgE and FcεRI, and is present in less than 10% of patients with CSU when strict criteria are used, that is, triple positivity of autologous serum skin test, immunoassays for IgG autoantibodies, and basophil activation tests.”
> “Mast cells are activated by IgE autoantibodies to autoallergens (type I autoallergy) or IgG-anti-IgE/IgG-anti-FcεRI autoantibodies (type IIb autoimmunity).”
> “Type I aiCSU is thought to be more common than type IIb aiCSU”

Source: [Kolkhir et al. (2022b)](https://doi.org/10.1016/j.jaci.2022.04.010)

<a id="topic-2.2.1.4-5"></a>

### Type I autoallergic CSU: IgE autoantibodies to thyroid peroxidase and other autoantigens

> “elevated IgE-anti-TPO levels in 54% (259) and 61% (191) of 478 patients with CSU, respectively.”
> “In total, patients with CSU have IgE to more than 200 autoantigens, which is more prevalent and different than seen in healthy controls”

Source: [Kolkhir et al. (2022b)](https://doi.org/10.1016/j.jaci.2022.04.010)

<a id="topic-2.2.1.4-6"></a>

### Type IIb autoimmune CSU: 8% meeting all three criteria in a multinational study of 182 participants

> “This was a multinational, multicenter study of 182 CSU patients.”
> “Of the 182 patients, 107 (59%) were ASST+, 46 (25%) were BASO+, and 105 (58%) were IgG anti-FcεRI+/IgE+.”
> “Fifteen patients (8%) fulfilled all three criteria of aiCSU.”
> “aiCSU patients appeared more severe (UAS7 21 vs 9 P < 0.016) but showed no other clinical or demographic differences from non-aiCSU patients.”
> “aiCSU patients also had markedly lower total IgE levels (P < 0.0001) and higher IgG anti-TPO levels (P < 0.001).”
> “Of biomarkers, positive BAT and BHRA tests were 69% and 88% predictive of aiCSU, respectively.”

Source: [Schoepke et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31228881/)

<a id="topic-2.2.1.4-7"></a>

### Type IIb autoimmune CSU: prevalence by number of positive markers

> “IgG-anti-FcεRI and/or IgG-anti-IgE were reported in 0% to 69% of patients with CSU, with most studies reporting rates of more than 20% and less than 50%”
> “Although these rates are higher as compared with less than 10% in the PURIST study, definition of type IIb aiCSU in these older studies was based on 1 to 2 markers only as compared with the PURIST study (all 3 markers, ie, ASST, basophil tests, and IgG autoantibodies immunoassay).”
> “However, the strict criteria for type IIb aiCSU used in the PURIST study do not imply that the rest of the patients with just 1 positive biomarker or 2 cannot have a type IIb response.”

Source: [Kolkhir et al. (2022b)](https://doi.org/10.1016/j.jaci.2022.04.010)

> “Chronic spontaneous urticaria (CSU) is believed to be Autoimmune (aiCSU) (type IIb CSU) in at least 8% of patients, associated with mast cell-activating IgG autoantibodies.”

Source: [Moñino-Romero et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37286132/)

<a id="topic-2.2.1.4-8"></a>

### Biomarkers of type IIb autoimmune CSU: low total IgE, elevated IgG-anti-TPO, basopenia, eosinopenia, and basophil tests

> “Type IIb autoimmune CSU is characterized by higher disease severity, concomitant autoimmune diseases, low levels of total IgE, elevated levels of IgG-anti–thyroid peroxidase, basopenia, eosinopenia, poor response to antihistamines and to omalizumab, and a good response to cyclosporine.”

Source: [Kolkhir et al. (2022b)](https://doi.org/10.1016/j.jaci.2022.04.010)

> “We analyzed records of patients with CSU from 2 independent cohorts (n = 1120) for demographic, clinical, and laboratory parameters and treatment responses.”
> “Cutoff values were greater than or equal to 34 kU/L (high aTPO) and less than 40 IU/mL (low total IgE).”
> “One of 10 patients with CSU had both high aTPO and low IgE (aTPO↑IgE↓, 11%, n = 123).”
> “Almost half the patients with aTPO↑IgE↓ (44%, 19 of 43) had a positive BAT result, the best single marker for aiCSU, versus 12% (43 of 344) of patients without aTPO↑IgE↓ (P < .001).”
> “Patients with aTPO↑IgE↓ showed low response rates to antihistamine treatment as compared with patients without aTPO↑IgE↓ (30% vs 47%; P = .01).”

Source: [Kolkhir et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34363991/)

> “Of 1,058 records found in the search, 94 studies were reviewed by experts in urticaria and 42 were included in the analysis.”
> “In CSU patients, BAT/BHRA+ showed a strong level of evidence for an association with high disease activity and low levels of total IgE.”
> “A weak level of evidence was shown for the association of BAT/BHRA+ and the presence of angioedema, and basopenia.”

Source: [Moñino-Romero et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37286132/)

<a id="topic-2.2.1.4-9"></a>

### Biomarkers in clinical practice: total IgE and IgG-anti-TPO, with limited diagnostic accuracy

> “In patients under specialist care, additional tests, such as total IgE and IgG‐anti‐TPO may be performed, as they indicate the likelihood of response to omalizumab”
> “Despite the established statistical association, the diagnostic performance and predictive accuracy of these tests remains limited”
> “However, although a clinical association between these laboratory markers and urticaria endotypes has been demonstrated, their clinical usefulness remains limited because there are no studies evaluating their diagnostic accuracy.”
> “Currently, cutoff points can be suggested but cannot be recommended for definitive endotype classification”
> “Validated biomarkers assays are currently under development and are needed to better assist in decision‐making.”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.1.4-10"></a>

### KIT and stem cell factor: mast cell dependence on SCF/KIT signaling for survival and maturation

> “Mast cells show exceptional dependence on SCF/c-Kit signaling for tissue survival, proliferation, migration, and terminal maturation.”
> “Loss of function mutations in c-Kit or c-Kitl produce profound tissue mast-cell deficiency, and administration of SCF expands mast-cell populations in vivo”
> “SCF is widely regarded as the main growth factor for mast cells, controlling nearly every stage of mast cell biology, including progenitor differentiation, proliferation of immature and mature cells, survival through inhibition of apoptosis, chemotaxis, adhesion, and effector activation, such as degranulation and cytokine release”
> “SCF amplifies IgE/FcϵRI-dependent mast cell activation mainly by lowering the activation threshold and enhancing downstream signaling, rather than triggering strong degranulation on its own.”

Source: [Ocadiz-Ruiz et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13755836/)

> “MCs express the tyrosine kinase receptor c-Kit, which binds stem cell factor (SCF), a key regulator of MC differentiation, maturation, proliferation and survival.”
> “SCF has also been implicated in MC activation, both as a direct trigger of degranulation and as an amplifier”
> “However, the reported effects of SCF on MC mediator release are variable with some studies describing comparable levels of mediator release following SCF and anti-IgE stimulation, whereas others report a weaker response to SCF.”

Source: [Jahn et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13729876/)

<a id="topic-2.2.1.4-11"></a>

### KIT expression beyond mast cells: melanocytes, hematopoietic progenitors, germ cells, and taste cells

> “These include hematopoietic progenitors, melanocytes, germ cells, and mast cells, which all are significantly affected by loss-of-function mutations of KIT or SCF”
> “Many other cells can express KIT constitutively or during immune responses, including dendritic cells, eosinophils, ILC2 cells, and taste cells.”

Source: [Tsai et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9177781/)

> “c-Kit is expressed by hematopoietic stem cells, melanocytes, progenitor cells, mast cells, eosinophils, dendritic cells, basophils, and innate lymphoid cells.”

Source: [Ocadiz-Ruiz et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13755836/)

<a id="topic-2.2.1.4-12"></a>

### Mast cell depletion through KIT as a therapeutic mechanism

> “These include monoclonal antibodies and small molecules that can specifically inhibit mast cell degranulation via key receptors (such as FcεRI), that block specific signal transduction pathways involved in mast cell activation (for example, BTK), that silence mast cells via inhibitory receptors (such as Siglec-8) or that reduce mast cell numbers and prevent their differentiation by acting on the mast/stem cell growth factor receptor KIT.”

Source: [Kolkhir et al. (2022a)](https://pubmed.ncbi.nlm.nih.gov/34611316/)

> “Chronic urticaria (CU) is a mast cell (MC)-dependent disease with limited therapeutic options.”
> “Current management strategies are directed at inhibiting IgE-mediated activation of MCs and antagonizing effects of released mediators.”

Source: [Metz et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37605867/)

> “Current recommended and effective treatment options for urticaria aim to target mast cell mediators at the receptors on nerves and endothelia, mast cell releasability, or mast cell activation by autoimmune triggers among others.”
> “Novel treatments currently under development aim to better regulate Type 2 immunity, or silence mast cells via inhibitory receptors, or to reduce mast cell numbers.”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.1.4-13"></a>

### Gut microbiome: emerging and unresolved role

> “There is emerging evidence that changes in the gut microbiome may play a role in the pathophysiology of urticaria”
> “However, as with the chicken or the egg dilemma, it is not clear if these changes are the cause or the consequence of the disease.”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

## Related pages
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Terms and abbreviations](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations.md)
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Product information and disease description](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Clinical evidence](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Economic information and modeling report](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: References](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references.md)
